Jupiter Neurosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 148/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 0.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Jupiter Neurosciences Inc's Score
Industry at a Glance
Industry Ranking
148 / 404
Overall Ranking
276 / 4582
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Jupiter Neurosciences Inc Highlights
StrengthsRisks
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Overvalued
The company’s latest PE is -4.71, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 375.55K shares, decreasing 4.78% quarter-over-quarter.
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Ticker SymbolJUNS
CompanyJupiter Neurosciences Inc
CEORosen (Christer)
Websitehttps://jupiterneurosciences.com/
FAQs
What is the current price of Jupiter Neurosciences Inc (JUNS)?
The current price of Jupiter Neurosciences Inc (JUNS) is 1.100.
What is the symbol of Jupiter Neurosciences Inc?
The ticker symbol of Jupiter Neurosciences Inc is JUNS.
What is the 52-week high of Jupiter Neurosciences Inc?
The 52-week high of Jupiter Neurosciences Inc is --.
What is the 52-week low of Jupiter Neurosciences Inc?
The 52-week low of Jupiter Neurosciences Inc is --.
What is the market capitalization of Jupiter Neurosciences Inc?
The market capitalization of Jupiter Neurosciences Inc is 37.72M.
What is the net income of Jupiter Neurosciences Inc?
The net income of Jupiter Neurosciences Inc is -2.44M.
Is Jupiter Neurosciences Inc (JUNS) currently rated as Buy, Hold, or Sell?
According to analysts, Jupiter Neurosciences Inc (JUNS) has an overall rating of Buy, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Jupiter Neurosciences Inc (JUNS)?
The Earnings Per Share (EPS TTM) of Jupiter Neurosciences Inc (JUNS) is -0.233.